Table 2. Study design characteristics of preclinical multilaboratory studies.
| Author, Year | Disease model | Intervention | Study Outcomes | Secondary Outcomes | Reported Results | Recommendations for Future Research |
|---|---|---|---|---|---|---|
| Reimer et al., 1985 | Myocardial infarction | Verapamil and ibuprofen | Infarct size | Mortality, hemodynamic measures, pathological/histological features, regional blood flow | Null | Not reported |
| Crabbe et al., 1999 | Stimulant exposure | Cocaine | Locomotor activity | Mixed | Further preclinical testing | |
| Alam et al., 2009 | Polytrauma | Blood transfusion | Hemodynamic parameters | Mortality | Mixed across resuscitation products | Further preclinical testing |
| Spoerke et al., 2009 | Polytrauma | Lyophilized plasma | Residual clotting activity | Mortality, hemodynamic measures, total blood loss, coagulation profiles, inflammatory measures | Positive | Further preclinical testing |
| Jones et al., 2015 | Myocardial infarction | Ischemic preconditioning | Infarct size | Hemodynamic measures, regional blood flow, heart weight, troponin I, mean arterial pressure | Positive | Further preclinical testing |
| Llovera et al., 2015 | Stroke | Anti-CD49d antibody | Infarct size | Functional outcome, invasion of leukocytes to brain | Mixed across models (positive, null) | First-in-human clinical trial |
| Maysami et al., 2016 | Stroke | Interleukin-I receptor antagonist | Infarct size | Odema, functional outcome, mortality | Positive | Extensive clinical trial |
| Bramlett et al., 2016 | Traumatic brain injury | Erythropoietin | Cognitive outcomes, biomarkers, motor outcomes, neuropathology | Null | No further preclinical study | |
| Browning et al., 2016 | Traumatic brain injury | Levetiracetam | Cognitive outcomes, biomarkers, motor outcomes, neuropathology | Positive | Further preclinical testing and first-in-human clinical trial | |
| Dixon et al., 2016 | Traumatic brain injury | Cyclosporine | Cognitive outcomes, biomarkers, motor outcomes, neuropathology | Null | No further preclinical testing | |
| Gill et al., 2016 | Diabetes | Combined anti-CD3 +IL-1 blockade |
Blood glucose | Null | Pause clinical trial | |
| Mountney et al., 2016 | Traumatic brain injury | Simvastatin | Cognitive outcomes, biomarkers, motor outcomes, neuropathology | Null | No further preclinical study | |
| Shear et al., 2016 | Traumatic brain injury | Nicotinamide | Cognitive outcomes, biomarkers, motor outcomes, neuropathology | Null | No further preclinical study | |
| Arroyo-Araujo et al., 2019 | Autism spectrum disorder | mGluR1 antagonist (JNJ16259685) | Behavioural activity | Positive | Not reported | |
| Jha et al., 2020 | Traumatic brain injury | Glibenclamide | Cognitive outcomes, biomarkers, motor outcomes, neuropathology | Glucose level, drug levels | Mixed across models and outcomes (positive, null, and negative) | Further preclinical testing |
| Kliewer et al., 2020 | Opioid-induced respiratory depression | Morphine | Respiratory rate | Constipation | Null | Not reported |